Pyxis Oncology to Showcase Innovations at November Conferences
Pyxis Oncology, Inc. (NASDAQ: PYXS), based in Boston, is a pioneering clinical-stage company dedicated to developing innovative therapies for some of the most challenging cancers. The company has recently announced its participation in notable investor conferences coming up this November 2025, marking an important opportunity for stakeholders and the public to learn more about their cutting-edge work.
Upcoming Conferences
Taking place in November, Pyxis Oncology will engage with investors through two key conferences:
Guggenheim 2nd Annual Healthcare Innovation Conference
The first event on the agenda is the Guggenheim Healthcare Innovation Conference, set for November 10, where the management team will participate in a fireside chat at 2:30 PM Eastern Time. This gathering underscores the company's commitment to transparency and shareholder engagement, providing insights into their strategic direction and advancements.
Stifel 2025 Healthcare Conference
Shortly after, on November 11 at 4:00 PM ET, Pyxis will also be featured at the Stifel 2025 Healthcare Conference, another significant event that promotes discussions around emerging healthcare technologies and investment opportunities. These conferences will allow Pyxis to highlight recent achievements and ongoing projects that could help reshape cancer treatment.
Access to Live Webcasts
For those who cannot attend the conferences in person, Pyxis Oncology will provide live webcasts of both fireside chats. These will be accessible through the Events & Presentations section on their Investor Relations webpage, ensuring that shareholders and interested parties can stay updated no matter their location.
About Pyxis Oncology, Inc.
Founded with the mission to innovate, Pyxis Oncology is at the forefront of biopharmaceutical development. One of its leading candidates is micvotabart pelidotin (MICVO), a groundbreaking antibody-drug conjugate designed specifically for targeting an important component of the tumor microenvironment. This innovative therapy focuses on a three-part action mechanism: directly killing tumor cells, eliciting a bystander effect, and promoting immunogenic cell death.
Currently undergoing Phase 1 clinical trials, MICVO is aimed at treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors. This therapy is also being evaluated in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), which represents a robust step in improving treatment outcomes.
Advancements in Cancer Therapy
Pyxis Oncology is not just an innovator but a leader ready to tackle the complex challenges of treating difficult cancers. Their work is vital in helping patients gain access to new therapeutic options, transforming lives with the hope of improved survival rates and quality of care. With an unwavering focus on new solutions, the company is poised to contribute significantly to advancements in oncology.
Contact Information
For more details about Pyxis' innovative approaches and ongoing developments, you can visit their official website or connect with their Investor Relations team:
Email: IR@pyxisoncology.com
Media Inquiries:
Cailyn McCutcheon,
Real Chemistry
cmccutcheon@realchemistry.com
Frequently Asked Questions
What is Pyxis Oncology focused on?
Pyxis Oncology is dedicated to developing innovative therapeutics to treat difficult-to-treat cancers, focusing on enhancing treatment effectiveness and patient outcomes.
When are the upcoming investor conferences?
The investor conferences will take place on November 10 and 11, 2025, featuring discussions about the company’s advancements and strategic direction.
How can I access the live webcasts?
Live webcasts of the fireside chats will be available on the Events & Presentations page of Pyxis Oncology’s Investor Relations website.
What is MICVO?
Micvotabart pelidotin (MICVO) is a first-in-class antibody-drug conjugate targeting the tumor microenvironment to improve cancer treatment outcomes.
How can I contact Pyxis Oncology for more information?
You can reach them via email at IR@pyxisoncology.com for investor inquiries or cmccutcheon@realchemistry.com for media inquiries.